Earlier this year, one of the most important incentives in rare pediatric drug development came back to life. Now, Congress wants to make sure it never disappears again.

On September 14, 2026, a bipartisan group of Representatives introduced the Priority for Pediatric Cures Act. The bill would make the FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program permanent. As it stands today, the program is set to expire in September 2029.

Most people have never heard of a priority review voucher. Yet in rare disease research, it is one of the few tools that determines whether a therapy for a small patient population gets funded at all.

At Myrtelle, we believe the communities we serve deserve to know exactly how it works and why this bill matters.

A Small Incentive with a Big Job

When the FDA approves a therapy for a rare pediatric disease, the company behind it can receive a priority review voucher. The voucher can be redeemed later for priority review of a different drug application, shortening the FDA’s review goal from ten months to six.

The voucher is also transferable. A company can sell it on the open market, and past vouchers have fetched over $100 million.

That fundamentally changes the business case for rare disease development. When a board decides where to direct capital, a condition affecting a small group of children must compete against conditions affecting millions. The PRV gives rare pediatric programs value beyond their immediate patient population, turning “too small to fund” into “worth the investment.”

The Results Speak for Themselves

Since the program began in 2012, the FDA has awarded 63 vouchers. The impact has been transformative:

  • 90%+ of vouchers went to therapies for conditions that previously had no approved treatment.
  • 47 rare pediatric diseases now have treatments available because of this program (up from just four before it existed).

Behind every single one of those numbers is a family that finally received an option where none existed before.

Why “Permanent” Matters

Rare disease drug development can take up to 15 years. A program that risks expiring every few years creates instability that makes long-term research plans difficult to sustain.

We have already seen what happens when the program lapses. After expiring in December 2024, it was not restored until February 2026. During those 13 months, approximately 200 therapies in development risked losing their eligibility.

Representative Gus Bilirakis, who led the bill, put it simply:

“Drug development takes years, and innovators need certainty when making research decisions today.”

The bill has strong bipartisan support alongside backing from the National Organization for Rare Disorders (NORD), the Rare Foundation, the Biotechnology Innovation Organization (BIO), and the Rare Disease Company Coalition.

What It Means for Canavan Disease

MYR-101 holds Rare Pediatric Disease designation from the FDA. That designation is the exact mechanism that makes a program eligible for a voucher upon approval.

For Canavan families, this is not a policy footnote. Incentives like this keep rare disease programs moving forward when funding conversations get difficult. The science still has to stand on its own, the voucher simply ensures the science has a reason to be funded.

Where MYR-101 Stands Today

  • Regulatory Designations: MYR-101 holds RMAT (Regenerative Medicine Advanced Therapy), Rare Pediatric Disease, Orphan Drug, and Fast Track designations from the FDA.
  • FDA START Pilot Program: Active participation provides direct, ongoing communication with the FDA and a streamlined development path for MYR-101.
  • Nature Medicine Publication: Study results published in September 2025 confirmed that MYR-101 restored myelin and reduced toxic NAA levels in treated children.
  • Commercial Manufacturing: Manufacturing is underway with Charles River and Viralgen, ensuring commercial readiness when approval comes.

Looking Ahead

Our focus remains the path to the BLA submission for MYR-101. October is also Canavan Disease Awareness Month, a time to bring this community’s story to a wider audience.

Next month we will look at the Rare Disease Framework Initiative recently announced by the Food and Drug Administration in an effort to reset it’s relationship with the rare disease community and address specific challenges of rare disease development.

How You Can Get Involved

  • Contact Your Representative: Ask them to cosponsor the Priority for Pediatric Cures Act. Tell them why it matters to Canavan families.
  • Share This Issue: Most people have never heard of priority review vouchers. Help us educate others by sharing this update.
  • Support Community Organizations: The Cure Canavan Fund, the Canavan Foundation, and NTSAD provide direct support to families every day. Consider supporting their work.